Therapeutic plasma exchange in autoimmune neurological disorders: A comprehensive evaluation of clinical outcomes, safety, and long‐term disability using the modified Rankin scale

Abstract

AbstractIntroductionAutoimmune neurological diseases (ANDs) involve the immune system attacking the nervous system, leading to various symptoms. Therapeutic plasma exchange (TPE) is used to remove pathogenic autoantibodies, aiming to improve clinical outcomes.MethodsThis ambispective observational study included 99 patients with ANDs who underwent TPE from January 2018 to June 2022 at a tertiary care center in India. Clinical outcomes were measured using the modified Rankin Scale (mRS) scores at admission, post‐TPE, at 3‐months, 6‐months, and 1‐year follow‐up post‐discharge. Data were analyzed using Epi Info version 7.0.ResultsThe median mRS score improved significantly from 5 (IQR 4–5) before TPE to 3 (IQR 2–4) post‐TPE (p < 0.001). Complications occurred in 5.95% of procedures, with allergic reactions being the most common. The in‐hospital mortality rate was 9%.ConclusionTPE is a safe and effective treatment modality for autoimmune neurological diseases, especially in resource‐constrained settings. It aids in both symptomatic relief and reducing long‐term functional disability.